

Table 1 Risk of bias ratings for randomised controlled trials reporting safety outcomes

Author Year	RSG	AC	BPP	BOA	IOD	SR	OB	Overall
Abelin 1989 ¹	?	?	?	?	+	?	-	-
Ahluwalia 1998 ²	+	+	+	+	+	?	+	+
Ahluwalia 2002 ³	+	+	+	+	+	?	+	+
AKIA401 ⁴	?	?	?	?	+	?	+	?
Allen 2011 ⁵	+	?	+	+	+	?	+	?
Andrews 2016 ⁶	?	+	-	?	+	+	+	-
Anthenelli 2013 ⁷	+	+	+	+	+	+	+	+
Anthenelli 2016 ⁸	+	+	+	+	+	+	+	+
Anthonisen 1994 ⁹	?	?	-	?	+	+	+	-
Areechon 1988 ¹⁰	?	?	+	+	+	?	-	-
Aubin 2004 ¹¹	+	+	+	+	+	?	+	+
Aubin 2008 ¹²	+	+	-	-	+	+	?	-
Austin 2014 ¹³	?	?	?	?	+	?	+	?
Baker 2006 ¹⁴	+	+	-	+	+	?	+	-
Baker 2016 ¹⁵	+	-	-	-	+	+	+	-
Baldassarri 2018 ¹⁶	+	+	+	+	-	+	?	-
Batra 2005 ¹⁷	?	?	?	?	+	?	+	?
Benowitz 2018 ¹⁸	+	+	+	+	+	+	+	+
Bernstein 2011 ¹⁹	+	+	-	+	+	+	+	-
Bernstein 2015 ²⁰	+	+	-	+	+	+	+	-
Bernstein 2016 ²¹	+	?	-	+	+	+	+	-
Binnie 2007 ²²	+	?	-	?	-	?	+	-
Bloch 2010 ²³	-	-	?	?	-	?	+	-
Blondal 1999 ²⁴	+	+	+	+	+	?	+	+
Bohadana 2000 ²⁵	+	+	?	?	?	?	+	?
Bolliger 2000 ²⁶	+	?	?	?	+	?	+	?
Bolliger 2011 ²⁷	+	+	+	+	+	+	+	+
Boyle 1992 ²⁸	+	+	+	+	+	?	+	+
Brandon 2011 ²⁹	+	+	+	+	+	+	+	+
Brantmark 1973 ³⁰	?	?	?	?	?	?	+	?
Buchkremer 1988 ³¹	?	?	+	+	?	?	+	?
Bullen 2010 ³²	+	+	?	?	+	?	+	?
Bullen 2013 ³³	+	+	+	+	+	+	+	+
Burstein 2006 ³⁴	+	+	+	+	+	+	+	+
Caldwell 2014 ³⁵	+	+	+	+	-	?	+	-
Caldwell 2016 ³⁶	+	+	+	+	+	+	+	+
Campbell 1983 ³⁷	+	+	+	+	+	?	+	+

Author Year	RSG	AC	BPP	BOA	IOD	SR	OB	Overall
Campbell 1991 ³⁸	?	?	?	?	?	?	+	?
Campbell 1996 ³⁹	?	?	?	?	+	?	+	?
Caponnetto 2013 ⁴⁰	+	+	+	+	+	?	+	?
Carpenter 2011 ⁴¹	+	?	-	-	+	+	+	-
Carpenter 2017 ⁴²	?	?	-	?	+	+	+	-
Carson 2014 ⁴³	+	+	?	?	?	?	+	?
Chen 2013 ⁴⁴	?	?	?	?	+	?	+	?
Chengappa 2014 ⁴⁵	+	+	+	+	?	?	?	?
Christen 1984 ⁴⁶	?	?	?	?	+	?	+	?
Cinciripini 1996 ⁴⁷	?	?	?	?	?	?	+	?
Cinciripini 2013 ⁴⁸	?	?	?	?	+	?	?	?
Cinciripini 2018 ⁴⁹	+	+	+	+	+	+	+	+
Cooney 2009 ⁵⁰	+	+	?	+	+	+	+	?
Cosci 2015 ⁵¹	?	?	?	?	+	?	+	?
Covey 2007 ⁵²	+	+	+	+	-	?	+	-
Cox 2012 ⁵³	+	?	?	?	+	?	+	?
Cravo 2016 ⁵⁴	+	?	-	-	+	+	-	-
Croghan 2003 ⁵⁵	+	+	-	-	+	?	+	-
Cummings 2011 ⁵⁶	?	-	?	?	+	?	+	-
Cummins 2016 ⁵⁷	+	+	-	+	+	+	+	-
Dale 1995 ⁵⁸	?	?	+	+	+	?	+	?
Dale 2002 ⁵⁹	?	?	+	+	+	?	+	?
Dale 2007 ⁶⁰	+	?	+	+	?	?	+	?
Dalsgarð 2004 ⁶¹	+	+	?	?	+	?	+	?
Daughton 1991 ⁶²	?	?	+	+	?	?	+	?
Daughton 1999/TNSG 1991 ⁶³	?	?	?	?	+	?	+	?
Dautzenberg 2001 ⁶⁴	?	?	?	?	+	?	+	?
Davidson 1998 ⁶⁵	+	+	?	?	+	?	+	?
deJong 2018 ⁶⁶	?	+	+	+	+	+	+	?
Dogar 2018 ⁶⁷	+	+	+	+	+	+	+	+
Du 2015 ⁶⁸	?	?	-	-	+	+	+	-
Ebbert 2007 ⁶⁹	+	+	+	?	+	?	+	?
Ebbert 2009 ⁷⁰	+	+	+	+	+	?	+	+
Ebbert 2010 ⁷¹	+	+	+	+	?	+	+	?
Ebbert 2011 ⁷²	+	+	+	+	+	+	+	+
Ebbert 2013 ⁷³	+	+	+	+	-	?	+	-
Ebbert 2014 ⁷⁴	+	+	+	+	+	?	+	+
Ebbert 2015 ⁷⁵	+	+	+	+	+	+	+	+
Ebbert 2017 ⁷⁶	+	?	+	+	-	?	+	-

Author Year	RSG	AC	BPP	BOA	IOD	SR	OB	Overall
Ehrsam 1991 ⁷⁷	?	?	?	?	?	?	?	?
Eisenberg 2013 ⁷⁸	+	+	?	?	+	?	+	?
Eisenberg 2016 ⁷⁹	+	?	?	?	+	+	+	?
Ellerbeck 2018 ⁸⁰	+	+	-	-	+	+	+	-
Etter 2002 ⁸¹	+	?	-	-	+	?	+	-
Etter 2009 ⁸²	+	?	-	-	+	?	+	-
Evins 2001 ⁸³	?	?	?	?	+	?	+	?
Evins 2005 ⁸⁴	?	?	?	?	+	?	+	?
Evins 2007 ⁸⁵	?	?	+	+	+	?	+	?
Evins 2014 ⁸⁶	+	+	+	+	+	+	+	+
Fagerstrom 2010 ⁸⁷	+	+	+	+	+	+	+	+
Fatemi 2013 ⁸⁸	?	?	?	?	?	+	+	?
Fee 1982 ⁸⁹	?	?	?	?	?	?	+	?
Ferry 1992 ⁹⁰	?	?	?	?	?	?	+	?
Ferry 1994 ⁹¹	?	?	?	?	?	?	+	?
Fiore 1994A ⁹²	+	+	?	?	+	?	+	?
Fiore 1994B ⁹²	+	?	?	?	+	?	+	?
Fortmann 1995 ⁹³	?	?	?	?	?	?	+	?
Fossati 2007 ⁹⁴	?	?	?	?	+	?	+	?
Foulds 1993 ⁹⁵	?	-	+	?	-	?	+	-
Fouz-Rosón 2017 ⁹⁶	+	?	-	-	+	?	+	-
Fucito 2011 ⁹⁷	?	?	+	+	+	?	+	?
Gariti 2009 ⁹⁸	+	?	+	+	+	?	+	?
Garvey 2000 ⁹⁹	?	?	?	?	-	?	+	-
Garza 2011 ¹⁰⁰	+	+	+	+	+	+	+	+
George 2002 ¹⁰¹	?	?	?	?	?	?	+	?
George 2008 ¹⁰²	?	?	?	?	+	?	+	?
Ginsberg 1992 ¹⁰³	?	?	?	?	?	?	+	?
Glavas 2003A ¹⁰⁴	?	+	?	?	+	?	+	?
Glavas 2003B ¹⁰⁵	?	+	?	?	?	?	?	?
GlaxoSmithKline 2009 ¹⁰⁶	?	?	+	?	+	+	+	?
GlaxoSmithKline 2011 ¹⁰⁷	?	?	-	-	+	+	+	-
Glover 2002 ¹⁰⁸	+	+	+	+	?	?	+	?
Glover 2002 ¹⁰⁹	+	+	?	?	?	?	+	?
Gonzales 2001 ¹¹⁰	+	?	+	+	?	?	+	?
Gonzales 2006 ¹¹¹	+	+	+	+	+	+	+	+
Gonzales 2014 ¹¹²	+	?	?	?	+	+	+	?
Gourlay 1995 ¹¹³	?	?	+	+	+	?	+	?
Graham 2017 ¹¹⁴	+	+	-	-	+	?	+	-

Author Year	RSG	AC	BPP	BOA	IOD	SR	OB	Overall
Grant 2007 ¹¹⁵	?	?	?	?	+	?	+	?
Gray 2015 ¹¹⁶	?	+	+	+	-	+	+	-
Haarmann 2016 ¹¹⁷	+	+	+	+	?	+	+	?
Haggström 2006 ¹¹⁸	?	?	+	+	?	?	+	?
Hajek 2011 ¹¹⁹	+	?	+	+	+	+	+	?
Hajek 2013 ¹²⁰	?	?	+	+	+	+	+	?
Hajek 2015 ¹²¹	+	+	+	+	+	+	+	+
Hajek 2019 ¹²²	+	+	-	?	+	+	+	-
Hall 2009 ¹²³	?	+	-	-	+	+	+	-
Hall 2011 ¹²⁴	?	?	?	?	?	?	+	?
Hand 2002 ¹²⁵	?	-	-	-	?	?	+	-
Hanioka 2010 ¹²⁶	?	?	?	?	?	?	+	?
Harackiewicz 1988 ¹²⁷	?	?	-	-	+	?	+	-
Hatsukami 2004 ¹²⁸	+	?	?	?	-	?	+	-
Hawk 2012 ¹²⁹	?	?	+	+	+	+	+	?
Hays 1999 ¹³⁰	+	+	+	+	?	?	+	?
Hays 2001 ¹³¹	+	+	+	+	+	?	+	+
Hays 2009 ¹³²	?	?	?	?	?	?	?	?
Herrmann 2018 ¹³³	?	?	+	?	+	?	+	?
Hertzberg 2001 ¹³⁴	?	?	?	?	-	?	+	-
Heydari 2012 ¹³⁵	?	?	-	-	+	-	?	-
Hilberink 2011 ¹³⁶	?	?	-	?	+	+	+	-
Hilleman 1994 ¹³⁷	?	?	-	-	?	?	+	-
Hjalmarson 1984 ¹³⁸	?	?	+	+	+	?	+	?
Hjalmarson 1994 ¹³⁹	?	?	+	+	?	?	+	?
Hjalmarson 1997 ¹⁴⁰	+	+	+	+	+	?	+	+
Holt 2005 ¹⁴¹	+	?	+	+	-	?	+	-
Hong 2011 ¹⁴²	?	?	+	+	+	+	+	?
Howard-Pitney 1999 ¹⁴³	+	?	+	+	?	?	+	?
Hughes 1989 ¹⁴⁴	?	+	+	+	+	?	+	?
Hughes 1999 ¹⁴⁵	?	?	?	?	-	?	+	-
Hughes 2003 ¹⁴⁶	?	?	?	?	?	?	+	?
Hughes 2010 ¹⁴⁷	+	+	?	?	+	?	-	-
Hughes 2011 ¹⁴⁸	?	+	+	+	?	?	+	+
Hurt 1990 ¹⁴⁹	?	?	?	?	+	?	+	?
Hurt 1994 ¹⁵⁰	?	?	?	?	+	?	+	?
Hurt 1997 ¹⁵¹	?	?	?	?	?	?	+	?
Hurt 2003 ¹⁵²	+	?	?	?	?	?	+	?
Hurt 2018 ¹⁵³	+	?	+	+	-	+	+	-

Author Year	RSG	AC	BPP	BOA	IOD	SR	OB	Overall
ICRF 1994 ¹⁵⁴	?	+	+	+	+	?	+	?
Ikonomidis 2017 ¹⁵⁵	?	?	?	?	+	+	+	?
Jain 2014 ¹⁵⁶	?	?	?	?	+	?	+	?
Jamrozik 1984 ¹⁵⁷	?	+	+	+	?	?	+	?
Jarvis 1982 ¹⁵⁸	?	?	+	+	+	?	-	-
Jennings 2014 ¹⁵⁹	+	?	-	?	+	?	+	-
Jorenby 1995 ¹⁶⁰	+	?	?	+	+	?	+	?
Jorenby 1999 ¹⁶¹	+	?	?	?	+	?	+	?
Jorenby 2006 ¹⁶²	+	+	?	?	+	+	+	?
Joseph 1996 ¹⁶³	+	?	?	?	+	?	+	?
Joseph 2011 ¹⁶⁴	+	+	?	+	+	+	+	?
Kalman 2006 ¹⁶⁵	?	?	?	?	+	?	+	?
Kalman 2011 ¹⁶⁶	?	?	?	?	+	?	+	?
Karam-Hage 2011 ¹⁶⁷	+	+	+	+	+	?	+	+
Killen 1984 ¹⁶⁸	?	?	-	-	+	?	+	-
Killen 1999 ¹⁶⁹	?	?	+	+	+	?	+	?
Killen 2006 ¹⁷⁰	+	+	+	+	+	?	+	+
Klesges 2015 ¹⁷¹	+	+	-	?	+	+	+	-
Koegelenberg 2014 ¹⁷²	?	?	+	+	+	+	+	?
Kornitzer 1995 ¹⁷³	+	+	+	+	?	?	+	?
Kralikova 2002 ¹⁷⁴	?	?	?	?	?	?	+	?
Kupecz 1996 ¹⁷⁵	-	-	-	-	?	?	+	-
Lee 2013 ¹⁷⁶	+	+	-	+	+	+	+	-
Lee 2018 ¹⁷⁷	+	+	-	+	+	+	+	-
Leischow 1996 ¹⁷⁸	+	+	?	?	-	?	+	-
Lerman 2004 ¹⁷⁹	+	+	+	+	+	?	+	+
Lerman 2015 ¹⁸⁰	?	+	+	+	+	?	+	+
Levin 1994 ¹⁸¹	?	?	?	?	+	?	+	?
Levine 2010 ¹⁸²	?	?	?	?	-	?	+	-
Lewis 1998 ¹⁸³	+	+	+	+	?	?	+	?
Li 2009 ¹⁸⁴	+	?	?	?	-	?	+	-
Lindson-Hawley 2014 ¹⁸⁵	+	+	-	-	+	+	+	-
Litten 2013 ¹⁸⁶	+	+	+	+	+	+	+	+
Littlewood 2017 ¹⁸⁷	+	+	+	?	-	?	+	-
Llivina 1988 ¹⁸⁸	?	?	?	?	-	?	+	-
Marsh 2005 ¹⁸⁹	+	?	-	-	-	?	+	-
Masiero 2018 ¹⁹⁰	+	?	?	?	+	+	+	?
McCarthy 2008 ¹⁹¹	+	+	+	+	+	?	+	+
McClure 2013 ¹⁹²	+	+	+	-	+	+	+	-

Author Year	RSG	AC	BPP	BOA	IOD	SR	OB	Overall
Ratner 2004 ²³¹	+	+	-	+	+	?	+	-
Ray 2014 ²³²	?	?	?	?	+	?	+	?
Reid 2003 ²³³	+	+	-	?	+	?	+	-
Rennard 1994 ²³⁴	?	+	?	?	+	?	+	?
Rennard 2006 ²³⁵	?	?	?	?	-	?	+	-
Rennard 2012 ²³⁶	+	+	+	+	+	+	+	+
Richmond 1994 ²³⁷	+	+	?	?	+	?	+	?
Rigotti 2006 ²³⁸	+	+	+	+	+	?	+	+
Rigotti 2010 ²³⁹	+	+	+	+	+	+	+	+
Rodriguez-Artalejo 2003 ²⁴⁰	+	+	-	-	+	?	+	-
Rohsenow 2017 ²⁴¹	+	+	?	+	?	+	+	?
Rose 1990 ²⁴²	?	?	?	?	-	?	+	-
Rose 2009 ²⁴³	?	?	+	+	-	?	+	-
Rose 2013 ²⁴⁴	?	?	?	?	+	+	?	?
Rose 2014 ²⁴⁵	?	?	?	?	+	+	+	?
Rose 2017 ²⁴⁶	?	?	?	?	+	+	+	?
Rovina 2009 ²⁴⁷	?	?	-	-	?	?	+	-
Rungruanghiranya 2008 ²⁴⁸	?	+	+	+	+	?	+	?
Russell 1983 ²⁴⁹	-	-	-	-	+	?	+	-
Rutgers 2011 ²⁵⁰	+	+	+	+	+	+	+	+
Sachs 1993 ²⁵¹	?	?	?	?	?	?	+	?
SadrAzodi 2009 ²⁵²	?	+	-	?	+	+	+	-
Schacht 2014 ²⁵³	+	?	+	+	?	?	+	?
Schmitz 2007 ²⁵⁴	+	+	?	?	+	?	+	?
Schneider 1983A ²⁵⁵	?	?	?	?	?	?	+	?
Schneider 1995 ²⁵⁶	?	?	?	?	?	?	+	?
Schneider 1996 ²⁵⁷	+	+	+	+	?	?	+	?
Schnoll 2010A ²⁵⁸	+	?	+	+	+	?	+	?
Schnoll 2010B ²⁵⁹	?	?	-	-	+	?	-	-
Schnoll 2013 ²⁶⁰	?	?	?	?	+	?	+	?
Schnoll 2015 ²⁶¹	+	?	?	?	+	+	+	?
Schnoll 2019 ²⁶²	+	+	+	+	+	+	+	+
Schuermans 2004 ²⁶³	+	+	+	+	+	?	+	+
Selby 2003 ²⁶⁴	?	?	?	?	-	?	+	-
SelmaBozkurtZincir 2013 ²⁶⁵	?	?	-	?	?	?	+	-
Severson 2015 ²⁶⁶	?	?	-	?	+	+	+	-
Sharma 2018 ²⁶⁷	+	+	-	?	+	+	+	-
Sheng 2013 ²⁶⁸	+	?	+	+	+	?	+	?
Sherman 2008 ²⁶⁹	-	+	-	-	?	?	+	-

Author Year	RSG	AC	BPP	BOA	IOD	SR	OB	Overall
Shiffman 2002 ²⁷⁰	?	?	?	?	+	?	+	?
Shiffman 2006 ²⁷¹	+	+	+	?	+	?	+	?
Shiffman 2009 ²⁷²	+	?	?	?	?	?	+	?
Shim 2012 ²⁷³	?	?	+	+	+	+	+	?
Shoptaw 2008 ²⁷⁴	?	?	?	?	-	?	+	-
Siddiqi 2013 ²⁷⁵	+	+	-	-	+	?	-	-
Simon 1997 ²⁷⁶	+	+	-	?	+	?	+	-
Simon 2004 ²⁷⁷	+	?	?	?	+	?	+	?
Simon 2009 ²⁷⁸	+	?	+	+	+	?	+	?
Singh 2010 ²⁷⁹	?	?	-	-	?	?	+	-
Smith 2009 ²⁸⁰	?	?	-	-	+	?	+	-
Smith 2016 ²⁸¹	+	?	+	+	+	+	+	?
SMK20001 ²⁸²	?	?	?	?	+	?	+	?
Sonderskov 1997 ²⁸³	+	+	+	+	+	?	+	+
Sorensen 2003 ²⁸⁴	?	+	-	+	+	?	+	-
SouthernIllinoisUniversityCarbondale 2005 ²⁸⁵	+	+	+	+	+	+	+	+
StanfordUniversity 2011 ²⁸⁶	?	?	+	?	+	+	+	?
Stapleton 1995 ²⁸⁷	+	+	+	+	?	+	+	?
Stapleton 2011 ²⁸⁸	+	?	+	+	-	+	+	-
Stapleton 2013 ²⁸⁹	+	+	-	-	+	?	+	-
Stein 2013 ²⁹⁰	?	?	+	+	+	+	+	?
Steinberg 2009 ²⁹¹	+	+	-	-	+	+	+	-
Steinberg 2011 ²⁹²	+	+	+	+	?	+	+	?
Steinberg 2018 ²⁹³	+	?	+	+	-	+	+	-
Sutherland 1992 ²⁹⁴	?	?	+	+	?	?	+	?
Swan 2003 ²⁹⁵	+	+	-	-	+	?	+	-
Tashkin 2001 ²⁹⁶	+	+	?	?	+	?	+	?
Tashkin 2011 ²⁹⁷	?	?	?	?	?	?	+	?
Thomsen 2010 ²⁹⁸	?	+	-	+	+	?	+	-
Thorsteinsson 2001 ²⁹⁹	?	?	?	?	-	?	+	-
Tidey 2011 ³⁰⁰	+	?	+	?	+	+	+	?
Tonnesen 1988 ³⁰¹	?	?	?	?	+	?	+	?
Tonnesen 1988 ³⁰²	?	?	-	-	+	?	+	-
Tonnesen 1991 ³⁰³	+	+	+	+	+	?	+	+
Tonnesen 1993 ³⁰⁴	+	+	+	+	+	?	+	+
Tonnesen 1999 ³⁰⁵	+	+	+	+	+	?	+	+
Tonnesen 2000 ³⁰⁶	+	?	?	?	?	?	+	?
Tonnesen 2003 ³⁰⁷	+	+	?	?	+	?	+	?

Author Year	RSG	AC	BPP	BOA	IOD	SR	OB	Overall
Tonnesen 2006 ³⁰⁸	+	?	?	?	+	?	+	?
Tønnesen 2012 ³⁰⁹	+	+	+	+	+	?	+	+
Tonstad 2003 ³¹⁰	?	?	?	?	?	?	+	?
Tonstad 2006 ³¹¹	+	+	+	+	+	+	+	+
Tsai 2007 ³¹²	+	+	+	+	?	?	+	?
Tseng 2016 ³¹³	+	+	+	+	+	?	+	+
Tsukahara 2010 ³¹⁴	?	?	-	-	?	+	+	-
Tuisku 2016 ³¹⁵	+	?	-	-	+	+	-	-
Tulloch 2016 ³¹⁶	+	+	-	+	+	+	+	-
Tzivoni 1998 ³¹⁷	?	?	?	?	+	?	+	?
UniversityofMichigan 2011 ³¹⁸	?	?	-	-	+	?	+	-
Uyar 2007 ³¹⁹	?	?	-	-	?	?	+	-
Velicer 2006 ³²⁰	+	?	-	+	+	?	+	-
Verplaetse 2016 ³²¹	?	?	?	?	?	?	+	?
Wagena 2005 ³²²	+	+	?	?	+	?	+	?
Wallstrom 2000 ³²³	+	?	+	+	?	?	+	?
Wang 2009 ³²⁴	?	?	?	?	?	+	+	?
Ward 2013 ³²⁵	?	+	+	+	+	?	+	?
Warner 2005 ³²⁶	?	?	+	+	?	?	+	?
Weaver 2015 ³²⁷	?	?	-	?	?	?	+	-
Weinberger 2008 ³²⁸	?	?	?	?	+	?	+	?
Weiner 2011 ³²⁹	?	?	?	?	+	?	+	?
Weiner 2012 ³³⁰	?	?	?	?	+	+	+	?
Wennike 2003 ³³¹	?	?	?	?	-	?	+	-
Westergaard 2015 ³³²	?	?	?	?	?	?	+	?
Westman 1993 ³³³	?	?	+	+	+	?	+	?
Whelton 2012 ³³⁴	+	?	-	+	+	+	+	-
Wiggers 2006 ³³⁵	+	?	?	+	+	?	+	?
Williams 2007 ³³⁶	?	?	?	?	+	+	+	?
Williams 2012 ³³⁷	?	?	+	+	+	+	+	?
Wilson 2008 ³³⁸	+	?	-	+	+	?	+	-
Winhusen 2014 ³³⁹	?	?	-	?	+	+	+	-
Wiratmoko 2013 ³⁴⁰	?	?	-	?	?	?	+	-
Wittchen 2011 ³⁴¹	?	-	-	-	+	?	+	-
Wolfenden 2005 ³⁴²	+	+	-	+	+	?	+	-
Wong 1999 ³⁴³	+	+	-	-	+	?	+	-
Wong 2012 ³⁴⁴	+	+	+	+	+	+	+	+
Wong 2017 ³⁴⁵	+	+	-	-	+	+	+	-
YaleUniversity 2007 ³⁴⁶	?	?	+	+	+	+	+	?

Author Year	RSG	AC	BPP	BOA	IOD	SR	OB	Overall
Zellweger 2005 ³⁴⁷	?	?	?	?	?	?	+	?
Zernig 2008 ³⁴⁸	?	+	-	?	-	+	+	-
Zhu 2016 ³⁴⁹	?	?	+	?	+	?	+	?
ZYB 30011 ³⁵⁰	?	?	?	?	+	?	+	?
ZYB40005 ³⁵¹	?	?	?	?	-	?	+	-
ZYB40030 ³⁵⁰	?	?	?	?	-	?	+	-
ZYBAKIA402 ³⁵²	?	?	?	?	+	?	+	?

Note. "+" = low risk of bias; "?" = unclear risk of bias; "-" = high risk of bias; RSG, random sequence generation; AC, allocation concealment; BPP, blinding of participants and personnel; BOA, blinding of outcome assessment; IOD, incomplete outcome data; SR, selective reporting; OB, other bias; Overall, overall risk of bias.

- Abelin T, Buehler A, Muller P, Vesanen K, Imhof PR. Controlled trial of transdermal nicotine patch in tobacco withdrawal. *Lancet*. 1989;1(8628):7-10.
- Ahluwalia JS, McNagny SE, Clark WS. Smoking cessation among inner-city African Americans using the nicotine transdermal patch. *J Gen Intern Med*. 1998;13(1):1-8.
- Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. *JAMA*. 2002;288(4):468-74.
- AKIA401: A single-center evaluation of Wellbutrin (bupropion hydrochloride) versus placebo as an aid to smoking cessation in heavy smokers (study 401).
- Allen MH, Debanne M, Lazignac C, Adam E, Dickinson LM, Damsa C. Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study. *Am J Psychiatry*. 2011;168(4):395-9.
- Andrews JO, Mueller M, Dooley M, Newman SD, Magwood GS, Tingen MS. Effect of a smoking cessation intervention for women in subsidized neighborhoods: A randomized controlled trial. *Prev Med*. 2016;90:170-6.
- Anthenelli RM, Morris C, Ramey TS, Dubrava SJ, Tsilkos K, Russ C, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. *Ann Intern Med*. 2013;159(6):390-400.
- Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. *Lancet*. 2016;387(10037):2507-20.
- Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. *Jama*. 1994;272(19):1497-505.
- Areechon W, Punnotok J. Smoking Cessation through the Use of Nicotine Chewing Gum - a Double-Blind Trial in Thailand. *Clinical Therapeutics*. 1988;10(2):183-6.
- Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. *Addiction*. 2004;99(9):1206-18.
- Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB, Jr., Gong J, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. *Thorax*. 2008;63(8):717-24.
- Austin AJ, Duka T, Rusted J, Jackson A. Effect of varenicline on aspects of inhibitory control in smokers. *Psychopharmacology (Berl)*. 2014;231(18):3771-85.
- Baker A, Richmond R, Haile M, Lewin TJ, Carr VJ, Taylor RL, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. *American Journal of Psychiatry*. 2006;163(11):1934-42.
- Baker TB, Piper ME, Stein JH, Smith SS, Bolt DM, Fraser DL, et al. Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. *JAMA*. 2016;315(4):371-9.

16. Baldassarri SR, Bernstein SL, Chupp GL, Slade MD, Fucito LM, Toll BA. Electronic cigarettes for adults with tobacco dependence enrolled in a tobacco treatment program: A pilot study. *Addict Behav.* 2018;80:1-5.
17. Batra A, Klingler K, Landfeldt B, Friederich HM, Westin A, Danielsson T. Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study. *Clin Pharmacol Ther.* 2005;78(6):689-96.
18. Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, et al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. *JAMA Intern Med.* 2018;178(5):622-31.
19. Bernstein SL, Bijur P, Cooperman N, Jearld S, Arnsten JH, Moadel A, et al. A randomized trial of a multicomponent cessation strategy for emergency department smokers. *Acad Emerg Med.* 2011;18(6):575-83.
20. Bernstein SL, D'Onofrio G, Rosner J, O'Malley S, Makuch R, Busch S, et al. Successful Tobacco Dependence Treatment in Low-Income Emergency Department Patients: A Randomized Trial. *Ann Emerg Med.* 2015;66(2):140-7.
21. Bernstein SL, Rosner J, Toll B. A Multicomponent Intervention Including Texting to Promote Tobacco Abstinence in Emergency Department Smokers: A Pilot Study. *Acad Emerg Med.* 2016;23(7):803-8.
22. Binnie VI, McHugh S, Jenkins W, Borland W, Macpherson LM. A randomised controlled trial of a smoking cessation intervention delivered by dental hygienists: a feasibility study. *BMC Oral Health.* 2007;7:5.
23. Bloch B, Reshef A, Cohen T, Tafla A, Gathas S, Israel S, et al. Preliminary effects of bupropion and the promoter region (HTTLPR) serotonin transporter (SLC6A4) polymorphism on smoking behavior in schizophrenia. *Psychiatry Res.* 2010;175(1-2):38-42.
24. Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. *BMJ.* 1999;318(7179):285-8.
25. Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. *Arch Intern Med.* 2000;160(20):3128-34.
26. Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, et al. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. *BMJ.* 2000;321(7257):329-33.
27. Bolliger CT, Issa JS, Posadas-Valay R, Safwat T, Abreu P, Correia EA, et al. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. *Clin Ther.* 2011;33(4):465-77.
28. Boyle R, Severson H, Lichtenstein E, et al. Smokeless tobacco cessation with nicotine reduction: A placebo controlled trial [abstract]. Paper presented at: 121st Annual Meeting Location: San Francisco, CA. 1992.
29. Brandon TH, Drobos DJ, Unrod M, Heckman BW, Oliver JA, Roetzheim RC, et al. Varenicline effects on craving, cue reactivity, and smoking reward. *Psychopharmacology (Berl).* 2011;218(2):391-403.
30. Brantmark B, Ohlin P, Westling H. Nicotine-containing chewing gum as an anti-smoking aid. *Psychopharmacologia.* 1973;31(3):191-200.
31. Buchkremer G, Bents H, Horstmann M, Opitz K, Tölle R. Combination of behavioral smoking cessation with transdermal nicotine substitution. *Addictive Behaviors.* 1989;14(2):229-38.
32. Bullen C, Howe C, Lin RB, Grigg M, Laugesen M, McRobbie H, et al. Pre-cessation nicotine replacement therapy: pragmatic randomized trial. *Addiction.* 2010;105(8):1474-83.
33. Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic cigarettes for smoking cessation: A randomised controlled trial. *The Lancet.* 2013;382(9905):1629-37.
34. Burstein AH, Fullerton T, Clark DJ, Faessel HM. Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. *J Clin Pharmacol.* 2006;46(11):1234-40.
35. Caldwell BO, Adamson SJ, Crane J. Combination rapid-acting nicotine mouth spray and nicotine patch therapy in smoking cessation. *Nicotine Tob Res.* 2014;16(10):1356-64.
36. Caldwell BO, Crane J. Combination Nicotine Metered Dose Inhaler and Nicotine Patch for Smoking Cessation: A Randomized Controlled Trial. *Nicotine Tob Res.* 2016;18(10):1944-51.
37. Campbell IA. Comparison of 4 Methods of Smoking Withdrawal in Patients with Smoking Related Diseases. *British Medical Journal.* 1983;286(6365):595-7.
38. Campbell IA, Prescott RJ, Tjeder-Burton SM. Smoking cessation in hospital patients given repeated advice plus nicotine or placebo chewing gum. *Respir Med.* 1991;85(2):155-7.

39. Campbell IA, Prescott RJ, Tjeder-Burton SM. Transdermal nicotine plus support in patients attending hospital with smoking-related diseases: a placebo-controlled study. *Respir Med.* 1996;90(1):47-51.
40. Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, et al. Efficiency and Safety of an eElectronic cigarette (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. *PLoS One.* 2013;8(6):e66317.
41. Carpenter MJ, Hughes JR, Gray KM, Wahlquist AE, Saladin ME, Alberg AJ. Nicotine therapy sampling to induce quit attempts among smokers unmotivated to quit: a randomized clinical trial. *Arch Intern Med.* 2011;171(21):1901-7.
42. Carpenter MJ, Heckman BW, Wahlquist AE, Wagener TL, Goniewicz ML, Gray KM, et al. A Naturalistic, Randomized Pilot Trial of E-Cigarettes: Uptake, Exposure, and Behavioral Effects. *Cancer Epidemiol Biomarkers Prev.* 2017;26(12):1795-803.
43. Carson KV, Smith BJ, Brinn MP, Peters MJ, Fitridge R, Koblar SA, et al. Safety of varenicline tartrate and counseling versus counseling alone for smoking cessation: a randomized controlled trial for inpatients (STOP study). *Nicotine Tob Res.* 2014;16(11):1495-502.
44. Chen HK, Lan TH, Wu BJ. A double-blind randomized clinical trial of different doses of transdermal nicotine patch for smoking reduction and cessation in long-term hospitalized schizophrenic patients. *Eur Arch Psychiatry Clin Neurosci.* 2013;263(1):75-82.
45. Chengappa KN, Perkins KA, Brar JS, Schlicht PJ, Turkin SR, Hetrick ML, et al. Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry.* 2014;75(7):765-72.
46. Christen AG, McDonald JL, Jr., Olson BL, Drook CA, Stookey GK. Efficacy of nicotine chewing gum in facilitating smoking cessation. *J Am Dent Assoc.* 1984;108(4):594-7.
47. Cinciripini PM, Cinciripini LG, Wallfisch A, Haque W, Van Vunakis H. Behavior therapy and the transdermal nicotine patch: effects on cessation outcome, affect, and coping. *J Consult Clin Psychol.* 1996;64(2):314-23.
48. Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. *JAMA Psychiatry.* 2013;70(5):522-33.
49. Cinciripini PM, Minnix JA, Green CE, Robinson JD, Engelmann JM, Versace F, et al. An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use. *Addiction.* 2018.
50. Cooney NL, Cooney JL, Perry BL, Carbone M, Cohen EH, Steinberg HR, et al. Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum. *Addiction.* 2009;104(9):1588-96.
51. Cosci F, Ibrahim HM, Nannini A, Schruers K. Experimental study on the effects of anxiety sensitivity and somatosensory amplification on the response to the 35% CO(2) challenge in abstinent smokers. *Exp Clin Psychopharmacol.* 2015;23(6):464-76.
52. Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, LoDuca C, et al. A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. *Addiction.* 2007;102(8):1292-302.
53. Cox LS, Nollen NL, Mayo MS, Choi WS, Faseru B, Benowitz NL, et al. Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. *J Natl Cancer Inst.* 2012;104(4):290-8.
54. Cravo AS, Bush J, Sharma G, Savioz R, Martin C, Craige S, et al. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. *Regul Toxicol Pharmacol.* 2016;81 Suppl 1:S1-S14.
55. Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL, et al. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. *Nicotine Tob Res.* 2003;5(2):181-7.
56. Cummings KM, Hyland A, Carlin-Menter S, Mahoney MC, Willett J, Juster HR. Costs of giving out free nicotine patches through a telephone quit line. *J Public Health Manag Pract.* 2011;17(3):E16-23.
57. Cummins SE, Gamst AC, Brandstein K, Seymann GB, Klonoff-Cohen H, Kirby CA, et al. Helping Hospitalized Smokers: A Factorial RCT of Nicotine Patches and Counseling. *Am J Prev Med.* 2016;51(4):578-86.
58. Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. *JAMA.* 1995;274(17):1353-8.

59. Dale LC, Ebbert JO, Schroeder DR, Croghan IT, Rasmussen DF, Trautman JA, et al. Bupropion for the treatment of nicotine dependence in spit tobacco users: a pilot study. *Nicotine Tob Res.* 2002;4(3):267-74.
60. Dale LC, Ebbert JO, Glover ED, Croghan IT, Schroeder DR, Severson HH, et al. Bupropion SR for the treatment of smokeless tobacco use. *Drug Alcohol Depend.* 2007;90(1):56-63.
61. Dalsgareth OJ, Hansen NC, Soes-Petersen U, Evald T, Hoegholm A, Barber J, et al. A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. *Nicotine Tob Res.* 2004;6(1):55-61.
62. Daughton DM, Heatley SA, Prendergast JJ, Causey D, Knowles M, Rolf CN, et al. Effect of Transdermal Nicotine Delivery as an Adjunct to Low-Intervention Smoking Cessation Therapy - a Randomized, Placebo-Controlled, Double-Blind-Study. *Archives of Internal Medicine.* 1991;151(4):749-52.
63. Daughton DM, Fortmann SP, Glover ED, Hatsukami DK, Heatley SA, Lichtenstein E, et al. The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day. *Prev Med.* 1999;28(2):113-8.
64. Dautzenberg B, Ruff F, Vaucher M, Maillon P, Jacob N, Kienzler JL, et al. First demonstration of the good efficacy/safety ratio of Nicotinell® 1mg Lozenge (NL 1mg), a new form of nicotine substitution, by randomised clinical trial. *European Respiratory Journal.* 2001;18 Suppl 33:12s.
65. Davidson M, Epstein M, Burt R, Schaefer C, Whitworth G, McDonald A. Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation. *Archives of Family Medicine.* 1998;7(6):569-74.
66. de Jong B, Schuppers AS, Kruisdijk-Gerritsen A, Arbouw MEL, van den Oever HLA, van Zanten ARH. The safety and efficacy of nicotine replacement therapy in the intensive care unit: a randomised controlled pilot study. *Ann Intensive Care.* 2018;8(1):70.
67. Dogar O, Zahid R, Mansoor S, Kanaan M, Ahluwalia JS, Jawad M, et al. Varenicline versus placebo for waterpipe smoking cessation: a double-blind randomized controlled trial. *Addiction.* 2018;113(12):2290-9.
68. Du D, Borders J, Selmani A, Wawerczak W. A Pilot Study to Investigate the Efficacy of Nicotine Oral Soluble Film, Lozenge and Gum in Relief of Acute Smoking Cue-provoked Craving for Cigarette in Low Dependence Smokers. *Journal of Smoking Cessation.* 2015;10(2):87-95.
69. Ebbert JO, Dale LC, Patten CA, Croghan IT, Schroeder DR, Moyer TP, et al. Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users. *Nicotine Tob Res.* 2007;9(1):43-52.
70. Ebbert JO, Severson HH, Croghan IT, Danaher BG, Schroeder DR. A randomized clinical trial of nicotine lozenge for smokeless tobacco use. *Nicotine Tob Res.* 2009;11(12):1415-23.
71. Ebbert JO, Severson HH, Croghan IT, Danaher BG, Schroeder DR. A pilot study of mailed nicotine lozenges with assisted self-help for the treatment of smokeless tobacco users. *Addict Behav.* 2010;35(5):522-5.
72. Ebbert JO, Croghan IT, Severson HH, Schroeder DR, Hays JT. A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States. *Nicotine Tob Res.* 2011;13(9):820-6.
73. Ebbert JO, Croghan IT, Schroeder DR, Hurt RD. A randomized phase II clinical trial of high-dose nicotine patch therapy for smokeless tobacco users. *Nicotine Tob Res.* 2013;15(12):2037-44.
74. Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. *JAMA.* 2014;311(2):155-63.
75. Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C, McRae TD, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. *JAMA.* 2015;313(7):687-94.
76. Ebbert J, Croghan I, Hurt R, Schroeder D, Hays J. Varenicline for smoking cessation in light smokers 2017; 18(10):[2031-5 pp.]. Available from: <http://onlinelibrary.wiley.com/doi/10.1111/cla.12145>
77. Ehsam RE, Buhler A, Muller P, Mauli D, Schumacher PM, Howald H, et al. [Weaning of young smokers using a transdermal nicotine patch]. *Schweiz Rundsch Med Prax.* 1991;80(7):145-50.
78. Eisenberg MJ, Grandi SM, Gervais A, O'Loughlin J, Paradis G, Rinfret S, et al. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. *J Am Coll Cardiol.* 2013;61(5):524-32.
79. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, et al. Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome. *Circulation.* 2016;133(1):21-30.
80. Ellerbeck EF, Nollen N, Hutcheson TD, Phadnis M, Fitzgerald SA, Vacek J, et al. Effect of Long-term Nicotine Replacement Therapy vs Standard Smoking Cessation for Smokers With Chronic Lung Disease: A Randomized Clinical Trial. *JAMA Netw Open.* 2018;1(5):e181843.

81. Etter JF, Laszlo E, Zellweger JP, Perrot C, Perneger TV. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial. *J Clin Psychopharmacol*. 2002;22(5):487-95.
82. Etter JF, Huguelet P, Perneger TV, Cornuz J. Nicotine Gum Treatment Before Smoking Cessation A Randomized Trial. *Archives of Internal Medicine*. 2009;169(11):1028-34.
83. Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. *Nicotine Tob Res*. 2001;3(4):397-403.
84. Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. *J Clin Psychopharmacol*. 2005;25(3):218-25.
85. Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, et al. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. *J Clin Psychopharmacol*. 2007;27(4):380-6.
86. Evins AE, Cather C, Pratt SA, Pachas GN, Hoepfner SS, Goff DC, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. *JAMA*. 2014;311(2):145-54.
87. Fagerstrom K, Gilljam H, Metcalfe M, Tonstad S, Messig M. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. *BMJ*. 2010;341:c6549.
88. Fatemi SH, Yousefi MK, Kneeland RE, Liesch SB, Folsom TD, Thuras PD. Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study. *Schizophr Res*. 2013;146(1-3):376-8.
89. Fee WM, Stewart MJ. A controlled trial of nicotine chewing gum in a smoking withdrawal clinic. *Practitioner*. 1982;226(1363):148-51.
90. Ferry LH, Robbins AS, Scariati PD, Masterson A, Abbey DE, Burchette RJ. Enhancement of smoking cessation using the antidepressant bupropion hydrochloride [abstract 2670]. *Circulation*. 1992;86(4 Suppl 1):I-671.
91. Ferry LH, Burchette RJ. Efficacy of Bupropion for Smoking Cessation in Non Depressed Smokers. *Journal of Addictive Diseases*. 1994;13(4):249-.
92. Fiore MC, Kenford SL, Jorenby DE, Wetter DW, Smith SS, Baker TB. Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. *Chest*. 1994;105(2):524-33.
93. Fortmann SP, Killen JD. Nicotine Gum and Self-Help Behavioral Treatment for Smoking Relapse Prevention - Results from a Trial Using Population-Based Recruitment. *Journal of Consulting and Clinical Psychology*. 1995;63(3):460-8.
94. Fossati R, Apolone G, Negri E, Compagnoni A, La Vecchia C, Mangano S, et al. A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. *Arch Intern Med*. 2007;167(16):1791-7.
95. Foulds J, Stapleton J, Hayward M, Russell MA, Feyerabend C, Fleming T, et al. Transdermal nicotine patches with low-intensity support to aid smoking cessation in outpatients in a general hospital. A placebo-controlled trial. *Arch Fam Med*. 1993;2(4):417-23.
96. Fouz-Roson N, Montemayor-Rubio T, Almadana-Pacheco V, Montserrat-Garcia S, Gomez-Bastero AP, Romero-Munoz C, et al. Effect of 0.5 mg versus 1 mg varenicline for smoking cessation: a randomized controlled trial. *Addiction*. 2017;112(9):1610-9.
97. Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O'Malley SS. A preliminary investigation of varenicline for heavy drinking smokers. *Psychopharmacology (Berl)*. 2011;215(4):655-63.
98. Gariti P, Lynch K, Alterman A, Kampman K, Xie H, Varillo K. Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking. *J Subst Abuse Treat*. 2009;37(3):247-55.
99. Garvey AJ, Kinnunen T, Nordstrom BL, Utman CH, Doherty K, Rosner B, et al. Effects of nicotine gum dose by level of nicotine dependence. *Nicotine Tob Res*. 2000;2(1):53-63.
100. Garza D, Murphy M, Tseng LJ, Riordan HJ, Chatterjee A. A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. *Biol Psychiatry*. 2011;69(11):1075-82.
101. George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. *Biol Psychiatry*. 2002;52(1):53-61.
102. George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. *Biol Psychiatry*. 2008;63(11):1092-6.
103. Ginsberg D, Hall SM, Rosinski M. Partner support, psychological treatment, and nicotine gum in smoking treatment: an incremental study. *Int J Addict*. 1992;27(5):503-14.

104. Glavas D, Rumboldt M, Rumboldt Z. Smoking cessation with nicotine replacement therapy among health care workers: Randomized double-blind study. *Croatian Medical Journal*. 2003;44(2):219-24.
105. Glavas D, Rumboldt Z. [Smoking cessation using the transdermal nicotine system]. *Lijec Vjesn*. 2003;125(1-2):8-12.
106. GlaxoSmithKline. Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation. <https://ClinicalTrials.gov/show/NCT00985985>; 2009.
107. GlaxoSmithKline. Provoked Craving Relief Study by NRT. <https://ClinicalTrials.gov/show/NCT01476202>; 2011.
108. Glover ED, Glover PN, Franzon M, Sullivan CR, Cerullo CC, Howell RM, et al. A comparison of a nicotine sublingual tablet and placebo for smoking cessation. *Nicotine Tob Res*. 2002;4(4):441-50.
109. Glover ED, Glover PN, Sullivan CR, Cerullo CL, Hobbs G. A comparison of sustained-release bupropion and placebo for smokeless tobacco cessation. *Am J Health Behav*. 2002;26(5):386-93.
110. Gonzales DH, Nides MA, Ferry LH, Kustra RP, Jamerson BD, Segall N, et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. *Clin Pharmacol Ther*. 2001;69(6):438-44.
111. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA*. 2006;296(1):47-55.
112. Gonzales D, Hajek P, Pliamm L, Nackaerts K, Tseng LJ, McRae TD, et al. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. *Clin Pharmacol Ther*. 2014;96(3):390-6.
113. Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. *BMJ*. 1995;311(7001):363-6.
114. Graham AL, Papandonatos GD, Cha S, Erar B, Amato MS, Cobb NK, et al. Improving Adherence to Smoking Cessation Treatment: Intervention Effects in a Web-Based Randomized Trial. *Nicotine Tob Res*. 2017;19(3):324-32.
115. Grant KM, Kelley SS, Smith LM, Agrawal S, Meyer JR, Romberger DJ. Bupropion and nicotine patch as smoking cessation aids in alcoholics. *Alcohol*. 2007;41(5):381-91.
116. Gray KM, McClure EA, Baker NL, Hartwell KJ, Carpenter MJ, Saladin ME. An exploratory short-term double-blind randomized trial of varenicline versus nicotine patch for smoking cessation in women. *Addiction*. 2015;110(6):1027-34.
117. Haarmann H, Gossler A, Herrmann P, Bonev S, Nguyen XP, Hasenfuss G, et al. Effects of varenicline on sympatho-vagal balance and cue reactivity during smoking withdrawal: a randomised placebo-controlled trial. *Tob Induc Dis*. 2016;14:26.
118. Haggstrom FM, Chatkin JM, Sussenbach-Vaz E, Cesari DH, Fam CF, Fritscher CC. A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. *Pulm Pharmacol Ther*. 2006;19(3):205-9.
119. Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. *Arch Intern Med*. 2011;171(8):770-7.
120. Hajek P, Smith KM, Dhanji AR, McRobbie H. Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. *BMC Med*. 2013;11:140.
121. Hajek P, McRobbie H, Myers Smith K, Phillips A, Cornwall D, Dhanji AR. Increasing varenicline dose in smokers who do not respond to the standard dosage: a randomized clinical trial. *JAMA Intern Med*. 2015;175(2):266-71.
122. Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, et al. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. *N Engl J Med*. 2019;380(7):629-37.
123. Hall SM, Humfleet GL, Munoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. *Addiction*. 2009;104(6):1043-52.
124. Hall SM, Humfleet GL, Munoz RF, Reus VI, Prochaska JJ, Robbins JA. Using extended cognitive behavioral treatment and medication to treat dependent smokers. *Am J Public Health*. 2011;101(12):2349-56.
125. Hand S, Edwards S, Campbell IA, Cannings R. Controlled trial of three weeks nicotine replacement treatment in hospital patients also given advice and support. *Thorax*. 2002;57(8):715-8.
126. Hanioka T, Ojima M, Tanaka H, Naito M, Hamajima N, Matsuse R. Intensive smoking-cessation intervention in the dental setting. *J Dent Res*. 2010;89(1):66-70.
127. Harackiewicz JM, Blair LW, Sansone C, Epstein JA, Stuchell RN. Nicotine gum and self-help manuals in smoking cessation: an evaluation in a medical context. *Addict Behav*. 1988;13(4):319-30.

128. Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA, et al. Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. *Am J Med.* 2004;116(3):151-7.
129. Hawk LW, Jr., Ashare RL, Lohnes SF, Schlienz NJ, Rhodes JD, Tiffany ST, et al. The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial. *Clin Pharmacol Ther.* 2012;91(2):172-80.
130. Hays JT, Croghan IT, Schroeder DR, Offord KP, Hurt RD, Wolter TD, et al. Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. *Am J Public Health.* 1999;89(11):1701-7.
131. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. *Ann Intern Med.* 2001;135(6):423-33.
132. Hays JT, Hurt RD, Decker PA, Croghan IT, Offord KP, Patten CA. A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics. *Nicotine Tob Res.* 2009;11(7):859-67.
133. Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, et al. Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse. *Addict Biol.* 2019;24(4):765-76.
134. Hertzberg MA, Moore SD, Feldman ME, Beckham JC. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. *J Clin Psychopharmacol.* 2001;21(1):94-8.
135. Heydari G, Talischi F, Tafti SF, Masjedi MR. Quitting smoking with varenicline: parallel, randomised efficacy trial in Iran. *Int J Tuberc Lung Dis.* 2012;16(2):268-72.
136. Hilberink SR, Jacobs JE, Breteler MH, de Vries H, Grol RP. General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. *Patient Educ Couns.* 2011;83(1):120-4.
137. Hilleman DE, Mohiuddin SM, Delcore MG. Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine, and bupropion in smoking cessation. *J Clin Pharmacol.* 1994;34(3):222-4.
138. Hjalmarson AI. Effect of nicotine chewing gum in smoking cessation. A randomized, placebo-controlled, double-blind study. *JAMA.* 1984;252(20):2835-8.
139. Hjalmarson A, Franzon M, Westin A, Wiklund O. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. *Arch Intern Med.* 1994;154(22):2567-72.
140. Hjalmarson A, Nilsson F, Sjoström L, Wiklund O. The nicotine inhaler in smoking cessation. *Arch Intern Med.* 1997;157(15):1721-8.
141. Holt S, Timu-Parata C, Ryder-Lewis S, Weatherall M, Beasley R. Efficacy of bupropion in the indigenous Maori population in New Zealand. *Thorax.* 2005;60(2):120-3.
142. Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, et al. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. *Arch Gen Psychiatry.* 2011;68(12):1195-206.
143. Howard-Pitney B, Killen JD, Fortmann SP. Quitting chew: results from a randomized trial using nicotine patches. *Exp Clin Psychopharmacol.* 1999;7(4):362-71.
144. Hughes JR, Gust SW, Keenan RM, Fenwick JW, Healey ML. Nicotine vs placebo gum in general medical practice. *JAMA.* 1989;261(9):1300-5.
145. Hughes JR, Lesmes GR, Hatsukami DK, Richmond RL, Lichtenstein E, Jorenby DE, et al. Are higher doses of nicotine replacement more effective for smoking cessation? *Nicotine Tob Res.* 1999;1(2):169-74.
146. Hughes JR, Novy P, Hatsukami DK, Jensen J, Callas PW. Efficacy of nicotine patch in smokers with a history of alcoholism. *Alcohol Clin Exp Res.* 2003;27(6):946-54.
147. Hughes JR, Solomon LJ, Livingston AE, Callas PW, Peters EN. A randomized, controlled trial of NRT-aided gradual vs. abrupt cessation in smokers actively trying to quit. *Drug Alcohol Depend.* 2010;111(1-2):105-13.
148. Hughes JR, Rennard SI, Fingar JR, Talbot SK, Callas PW, Fagerstrom KO. Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial. *Nicotine Tob Res.* 2011;13(10):955-64.
149. Hurt RD, Lauger GG, Offord KP, Kottke TE, Dale LC. Nicotine-Replacement Therapy with Use of a Transdermal Nicotine Patch - a Randomized Double-Blind Placebo-Controlled Trial. *Mayo Clinic Proceedings.* 1990;65(12):1529-37.
150. Hurt RD, Dale LC, Fredrickson PA, Caldwell CC, Lee GA, Offord KP, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. *JAMA.* 1994;271(8):595-600.

151. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. *N Engl J Med.* 1997;337(17):1195-202.
152. Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ, et al. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. *J Clin Oncol.* 2003;21(5):914-20.
153. Hurt RT, Ebbert JO, Croghan IT, Schroeder DR, Hurt RD, Hays JT. Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: A randomized controlled trial. *Drug Alcohol Depend.* 2018;184:12-7.
154. Randomised trial of nicotine patches in general practice: results at one year. Imperial Cancer Research Fund General Practice Research Group. *BMJ.* 1994;308(6942):1476-7.
155. Ikonomidis I, Marinou M, Vlastos D, Kourea K, Andreadou I, Liarakos N, et al. Effects of varenicline and nicotine replacement therapy on arterial elasticity, endothelial glycocalyx and oxidative stress during a 3-month smoking cessation program. *Atherosclerosis.* 2017;262:123-30.
156. Jain R, Jhanjee S, Jain V, Gupta T, Mittal S, Goelz P, et al. A double-blind placebo-controlled randomized trial of varenicline for smokeless tobacco dependence in India. *Nicotine Tob Res.* 2014;16(1):50-7.
157. Jamrozik K, Fowler G, Vessey M, Wald N. Placebo controlled trial of nicotine chewing gum in general practice. *Br Med J (Clin Res Ed).* 1984;289(6448):794-7.
158. Jarvis MJ, Raw M, Russell MAH, Feyerabend C. Randomized Controlled Trial of Nicotine Chewing-Gum. *British Medical Journal.* 1982;285(6341):537-40.
159. Jennings C, Kotseva K, De Bacquer D, Hoes A, de Velasco J, Brusaferrero S, et al. Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial. *Eur Heart J.* 2014;35(21):1411-20.
160. Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP, Croghan IT, et al. Varying nicotine patch dose and type of smoking cessation counseling. *JAMA.* 1995;274(17):1347-52.
161. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *N Engl J Med.* 1999;340(9):685-91.
162. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA.* 2006;296(1):56-63.
163. Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. *N Engl J Med.* 1996;335(24):1792-8.
164. Joseph AM, Fu SS, Lindgren B, Rothman AJ, Kodl M, Lando H, et al. Chronic disease management for tobacco dependence: a randomized, controlled trial. *Arch Intern Med.* 2011;171(21):1894-900.
165. Kalman D, Kahler CW, Garvey AJ, Monti PM. High-dose nicotine patch therapy for smokers with a history of alcohol dependence: 36-week outcomes. *J Subst Abuse Treat.* 2006;30(3):213-7.
166. Kalman D, Herz L, Monti P, Kahler CW, Mooney M, Rodrigues S, et al. Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study. *Drug Alcohol Depend.* 2011;118(2-3):111-8.
167. Karam-Hage M, Strobbe S, Robinson JD, Brower KJ. Bupropion-SR for smoking cessation in early recovery from alcohol dependence: a placebo-controlled, double-blind pilot study. *Am J Drug Alcohol Abuse.* 2011;37(6):487-90.
168. Killen JD, Maccoby N, Taylor CB. Nicotine Gum and Self-Regulation Training in Smoking Relapse Prevention. *Behavior Therapy.* 1984;15(3):234-48.
169. Killen JD, Fortmann SP, Davis L, Strausberg L, Varady A. Do heavy smokers benefit from higher dose nicotine patch therapy? *Experimental and Clinical Psychopharmacology.* 1999;7(3):226-33.
170. Killen JD, Fortmann SP, Murphy GM, Jr., Hayward C, Arredondo C, Crompton D, et al. Extended treatment with bupropion SR for cigarette smoking cessation. *J Consult Clin Psychol.* 2006;74(2):286-94.
171. Klesges RC, Ebbert JO, Talcott GW, Thomas F, Richey PA, Womack C, et al. Efficacy of a Tobacco Quitline in Active Duty Military and TRICARE Beneficiaries: A Randomized Trial. *Mil Med.* 2015;180(8):917-25.
172. Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. *JAMA.* 2014;312(2):155-61.
173. Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. *Prev Med.* 1995;24(1):41-7.

174. Kralikova E, Kozak J, Rasmussen T, Cort N. The clinical benefits of NRT-supported smoking reduction. *Nicotine Tob Res.* 2002;4(243):20.
175. Kupecz D, Prochazka A. A comparison of nicotine delivery systems in a multimodality smoking cessation program. *Nurse Pract.* 1996;21(2):73, 7-8, 81 passim.
176. Lee SM, Landry J, Jones PM, Buhrmann O, Morley-Forster P. The effectiveness of a perioperative smoking cessation program: a randomized clinical trial. *Anesth Analg.* 2013;117(3):605-13.
177. Lee SM, Tenney R, Wallace AW, Arjomandi M. E-cigarettes versus nicotine patches for perioperative smoking cessation: a pilot randomized trial. *PeerJ.* 2018;6:e5609.
178. Leischow SJ, Nilsson F, Franzon M, Hill A, Otte P, Merikle EP. Efficacy of the nicotine inhaler as an adjunct to smoking cessation. *American Journal of Health Behavior.* 1996;20(5):364-71.
179. Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. *Ann Intern Med.* 2004;140(6):426-33.
180. Lerman C, Schnoll RA, Hawk LW, Jr., Cinciripini P, George TP, Wileyto EP, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. *Lancet Respir Med.* 2015;3(2):131-8.
181. Levin ED, Westman EC, Stein RM, Carnahan E, Sanchez M, Herman S, et al. Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. *J Clin Psychopharmacol.* 1994;14(1):41-9.
182. Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, et al. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. *Arch Intern Med.* 2010;170(6):543-50.
183. Lewis SF, Piasecki TM, Fiore MC, Anderson JE, Baker TB. Transdermal nicotine replacement for hospitalized patients: a randomized clinical trial. *Prev Med.* 1998;27(2):296-303.
184. Li J, Zhang T-I, Wang B, Li X-w. An efficacy analysis of bupropion for smoking cessation in schizophrenia. *Zhongguo Xinyao yu Linchuang Zazhi.* 2009;28(3):231-4.
185. Lindson-Hawley N, Coleman T, Docherty G, Hajek P, Lewis S, Lycett D, et al. Nicotine patch preloading for smoking cessation (the preloading trial): study protocol for a randomized controlled trial. *Trials.* 2014;15(296):296.
186. Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. *J Addict Med.* 2013;7(4):277-86.
187. Littlewood RA, Claus ED, Wilcox CE, Mickey J, Arenella PB, Bryan AD, et al. Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo. *Psychopharmacology (Berl).* 2017;234(23-24):3417-29.
188. Llivina TS, Tuya DM, Quintana JG, Torres CI, Barrera EC, Saez CM, et al. Smoking Cessation - Effectiveness of Nicotine Containing Chewing Gum - a Double-Blind Trial. *Medicina Clinica.* 1988;90(16):646-50.
189. Marsh HS, Dresler CM, Choi JH, Targett DA, Gamble ML, Strahs KR. Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions: a 12-week, randomized, open-label study. *Clin Ther.* 2005;27(10):1571-87.
190. Masiero M, Lucchiari C, Mazzocco K, Veronesi G, Maisonneuve P, Jemos C, et al. E-cigarettes May Support Smokers With High Smoking-Related Risk Awareness to Stop Smoking in the Short Run: Preliminary Results by Randomized Controlled Trial. *Nicotine Tob Res.* 2019;21(1):119-26.
191. McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC, et al. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. *Nicotine Tob Res.* 2008;10(4):717-29.
192. McClure EA, Vandrey RG, Johnson MW, Stitzer ML. Effects of varenicline on abstinence and smoking reward following a programmed lapse. *Nicotine Tob Res.* 2013;15(1):139-48.
193. McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. *Biol Psychiatry.* 2009;66(2):185-90.
194. Mercie P, Arsandaux J, Katlama C, Ferret S, Beuscart A, Spadone C, et al. Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial. *Lancet Hiv.* 2018;5(3):E126-E35.
195. Merz PG, Kellerstanislawski B, Huber T, Woodcock BG, Rietbrock N. Transdermal Nicotine in Smoking Cessation and Involvement of Nonspecific Influences. *International Journal of Clinical Pharmacology and Therapeutics.* 1993;31(10):476-82.
196. Meszaros ZS, Abdul-Malak Y, Dimmock JA, Wang D, Ajagbe TO, Batki SL. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial. *J Clin Psychopharmacol.* 2013;33(2):243-7.

197. Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL. Varenicline decreases alcohol consumption in heavy-drinking smokers. *Psychopharmacology (Berl)*. 2012;223(3):299-306.
198. Moller AM, Villebro N, Pedersen T, Tonnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. *Lancet*. 2002;359(9301):114-7.
199. Molyneux A, Lewis S, Leivers U, Anderton A, Antoniak M, Brackenridge A, et al. Clinical trial comparing nicotine replacement therapy (NRT) plus brief counselling, brief counselling alone, and minimal intervention on smoking cessation in hospital inpatients. *Thorax*. 2003;58(6):484-8.
200. Mori T STYGNMHT. A clinical trial of nicotine chewing gum for smoking cessation [abstract 428]. 1992.
201. Mulligan SC, Masterson JG, Devane JG, Kelly JG. Clinical and pharmacokinetic properties of a transdermal nicotine patch. *Clin Pharmacol Ther*. 1990;47(3):331-7.
202. Myles PS, Leslie K, Angliss M, Mezzavia P, Lee L. Effectiveness of bupropion as an aid to stopping smoking before elective surgery: a randomised controlled trial. *Anaesthesia*. 2004;59(11):1053-8.
203. Myung SK, Seo HG, Park S, Kim Y, Kim DJ, Lee DH, et al. Sociodemographic and smoking behavioral predictors associated with smoking cessation according to follow-up periods: a randomized, double-blind, placebo-controlled trial of transdermal nicotine patches. *J Korean Med Sci*. 2007;22(6):1065-70.
204. Nahvi S, Ning Y, Segal KS, Richter KP, Arnsten JH. Varenicline efficacy and safety among methadone maintained smokers: a randomized placebo-controlled trial. *Addiction*. 2014;109(9):1554-63.
205. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. *Clin Ther*. 2007;29(6):1040-56.
206. Fox Chase Cancer Center, National Cancer Institute. Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking. <https://ClinicalTrials.gov/show/NCT00365508>; 2006.
207. Pfizer. Long-term Varenicline Treatment for Smoking Cessation. University of Wisconsin, Madison: <https://ClinicalTrials.gov/show/NCT00828113>; 2009.
208. Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia. <https://ClinicalTrials.gov/show/NCT01010477>; 2009.
209. Duke University. Supplemental Nicotine Administration for Smoking Cessation in Posttraumatic Stress Disorder (PTSD). 2009.
210. Niaura R, Hays JT, Jorenby DE, Leone FT, Pappas JE, Reeves KR, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. *Curr Med Res Opin*. 2008;24(7):1931-41.
211. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. *Arch Intern Med*. 2006;166(15):1561-8.
212. Nides M, Danielsson T, Saunders F, Perfekt R, Kapikian R, Solla J, et al. Efficacy and safety of a nicotine mouth spray for smoking cessation; a randomized, multicenter, controlled study in a naturalistic setting. *Nicotine Tob Res*. 2018;18:18.
213. Nides M, Shanga GM, Bishop A, Becker WD. Nicotine Lozenges in the Relief of Behaviorally Provoked Craving. *Am J Health Behav*. 2018;42(3):69-80.
214. Olson LC, Hong D, Conell-Price JS, Cheng S, Flood P. A transdermal nicotine patch is not effective for postoperative pain management in smokers: a pilot dose-ranging study. *Anesth Analg*. 2009;109(6):1987-91.
215. O'Malley S, Zweben A, Fucito L, Wu R, Piepmeier M, Ockert D, et al. Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: a Randomized Clinical Trial 2017; 75(2):[129-38 pp.]. Available from: <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/299/CN-01457299/frame.html>.
216. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. *Arch Intern Med*. 2006;166(15):1571-7.
217. Oncken C, Cooney J, Feinn R, Lando H, Kranzler HR. Transdermal nicotine for smoking cessation in postmenopausal women. *Addict Behav*. 2007;32(2):296-309.
218. Pack QR, Jorenby DE, Fiore MC, Jackson T, Weston P, Piper ME, et al. A comparison of the nicotine lozenge and nicotine gum: an effectiveness randomized controlled trial. *WMJ*. 2008;107(5):237-43.
219. Paoletti P, Fornai E, Maggiorelli F, Puntoni R, Viegi G, Carrozzi L, et al. Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patch. *Eur Respir J*. 1996;9(4):643-51.

220. Pei H, Zhang LJ, Zeng LM, Yu F. Effect of preoperative smoking intervention on postoperative complications of total hip replacement. [Chinese]. *Chinese Journal of Evidence-Based Medicine*. 2014;14(4):399-403.
221. Perng RP, Hsieh WC, Chen YM, Lu CC, Chiang SJ. Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation. *J Formos Med Assoc*. 1998;97(8):547-51.
222. Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. *Arch Gen Psychiatry*. 2009;66(11):1253-62.
223. Piper ME, Cook JW, Schlam TR, Jorenby DE, Smith SS, Collins LM, et al. A Randomized Controlled Trial of an Optimized Smoking Treatment Delivered in Primary Care. *Ann Behav Med*. 2018;52(10):854-64.
224. Planer D, Lev I, Elitzur Y, Sharon N, Ouzan E, Pugatsch T, et al. Bupropion for smoking cessation in patients with acute coronary syndrome. *Arch Intern Med*. 2011;171(12):1055-60.
225. Plebani JG, Lynch KG, Rennert L, Pettinati HM, O'Brien CP, Kampman KM. Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. *Drug Alcohol Depend*. 2013;133(2):754-8.
226. Poling J, Rounsaville B, Gonsai K, Severino K, Sofuoglu M. The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. *Am J Addict*. 2010;19(5):401-8.
227. Ponciano-Rodriguez G, Paez-Martinez N, Villa-Romero A, Gutierrez-Grobe Y, Mendez-Sanchez N. Early changes in the components of the metabolic syndrome in a group of smokers after tobacco cessation. *Metab Syndr Relat Disord*. 2014;12(4):242-50.
228. Puska P, Bjorkqvist S, Koskela K. Nicotine-containing chewing gum in smoking cessation: a double blind trial with half year follow-up. *Addict Behav*. 1979;4(2):141-6.
229. Puska P, Korhonen HJ, Vartiainen E, Urjanheimo EL, Gustavsson G, Westin A. Combined use of nicotine patch and gum compared with gum alone in smoking cessation - a clinical trial in North Karelia. *Tobacco Control*. 1995;4(3):231-5.
230. Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. *BMC Med*. 2014;12(172):172.
231. Ratner PA, Johnson JL, Richardson CG, Bottorff JL, Moffat B, Mackay M, et al. Efficacy of a smoking-cessation intervention for elective-surgical patients. *Res Nurs Health*. 2004;27(3):148-61.
232. Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED. Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. *Psychopharmacology (Berl)*. 2014;231(19):3843-53.
233. Reid R, Pipe A, Higginson L, Johnson K, D'Angelo MS, Cooke D, et al. Stepped care approach to smoking cessation in patients hospitalized for coronary artery disease. *J Cardiopulm Rehabil*. 2003;23(3):176-82.
234. Rennard S, Daughton D, Cheney R, Thompson A, Miles R, Windle J, et al. Nicotine Replacement Therapy for Patients with Coronary-Artery Disease. *Archives of Internal Medicine*. 1994;154(9):989-95.
235. Rennard SI, Glover ED, Leischow S, Daughton DM, Glover PN, Muramoto M, et al. Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial. *Nicotine Tob Res*. 2006;8(4):555-64.
236. Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. *Nicotine Tob Res*. 2012;14(3):343-50.
237. Richmond RL, Harris K, Dealmeidaneto A. The Transdermal Nicotine Patch - Results of a Randomized Placebo-Controlled Trial. *Medical Journal of Australia*. 1994;161(2):130-&.
238. Rigotti NA, Thorndike AN, Regan S, McKool K, Pasternak RC, Chang Y, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. *Am J Med*. 2006;119(12):1080-7.
239. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. *Circulation*. 2010;121(2):221-9.
240. Rodriguez-Artalejo F, Lafuente Urdinguio P, Guallar-Castillon P, Garteizurrekoa Dublang P, Sainz Martinez O, Diez Azcarate JI, et al. One year effectiveness of an individualised smoking cessation intervention at the workplace: a randomised controlled trial. *Occup Environ Med*. 2003;60(5):358-63.
241. Rohsenow DJ, Tidey JW, Martin RA, Colby SM, Swift RM, Leggio L, et al. Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms. *Addiction*. 2017;112(10):1808-20.
242. Rose JE, Levin ED, Behm FM, Adivi C, Schur C. Transdermal nicotine facilitates smoking cessation. *Clin Pharmacol Ther*. 1990;47(3):323-30.

243. Rose JE, Herskovic JE, Behm FM, Westman EC. Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment. *Nicotine Tob Res.* 2009;11(9):1067-75.
244. Rose JE, Behm FM. Adapting smoking cessation treatment according to initial response to precessation nicotine patch. *Am J Psychiatry.* 2013;170(8):860-7.
245. Rose JE, Behm FM. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. *Am J Psychiatry.* 2014;171(11):1199-205.
246. Rose JE, Behm FM. Combination Varenicline/Bupropion Treatment Benefits Highly Dependent Smokers in an Adaptive Smoking Cessation Paradigm. *Nicotine Tob Res.* 2017;19(8):999-1002.
247. Rovina N, Nikoloutsou I, Katsani G, Dima E, Fransis K, Roussos C, et al. Effectiveness of pharmacotherapy and behavioral interventions for smoking cessation in actual clinical practice. *Ther Adv Respir Dis.* 2009;3(6):279-87.
248. Rungruanghiranya S, Ekpanyaskul C, Hattapornsawan Y, Tundulawessa Y. Effect of nicotine polyestex gum on smoking cessation and quality of life. *J Med Assoc Thai.* 2008;91(11):1656-62.
249. Russell MAH, Merriman R, Stapleton J, Taylor W. Effect of Nicotine Chewing Gum as an Adjunct to General-Practitioners Advice against Smoking. *British Medical Journal.* 1983;287(6407):1782-5.
250. Rutgers TSUoNJ, Pfizer. Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit. <https://ClinicalTrials.gov/show/NCT01308736>; 2011.
251. Sachs DPL, Sawe U, Leischow SJ. Effectiveness of a 16-Hour Transdermal Nicotine Patch in a Medical-Practice Setting, without Intensive Group-Counseling. *Archives of Internal Medicine.* 1993;153(16):1881-90.
252. Sadr Azodi O, Lindstrom D, Adami J, Tonnesen H, Nasell H, Gilljam H, et al. The efficacy of a smoking cessation programme in patients undergoing elective surgery: a randomised clinical trial. *Anaesthesia.* 2009;64(3):259-65.
253. Schacht JP, Anton RF, Randall PK, Li X, Henderson S, Myrick H. Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. *Psychopharmacology (Berl).* 2014;231(18):3799-807.
254. Schmitz JM, Stotts AL, Mooney ME, Delaune KA, Moeller GF. Bupropion and cognitive-behavioral therapy for smoking cessation in women. *Nicotine Tob Res.* 2007;9(6):699-709.
255. Schneider NG, Jarvik ME, Forsythe AB, Read LL, Elliott ML, Schweiger A. Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial. *Addict Behav.* 1983;8(3):253-61.
256. Schneider NG, Olmstead R, Mody FV, Doan K, Franzon M, Jarvik ME, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. *Addiction.* 1995;90(12):1671-82.
257. Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. *Addiction.* 1996;91(9):1293-306.
258. Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. *Ann Intern Med.* 2010;152(3):144-51.
259. Schnoll RA, Martinez E, Tatum KL, Glass M, Bernath A, Ferris D, et al. Nicotine patch vs. nicotine lozenge for smoking cessation: an effectiveness trial coordinated by the Community Clinical Oncology Program. *Drug Alcohol Depend.* 2010;107(2-3):237-43.
260. Schnoll RA, Wileyto EP, Leone FT, Tyndale RF, Benowitz NL. High dose transdermal nicotine for fast metabolizers of nicotine: a proof of concept placebo-controlled trial. *Nicotine Tob Res.* 2013;15(2):348-54.
261. Schnoll RA, Goelz PM, Veluz-Wilkins A, Blazekovic S, Powers L, Leone FT, et al. Long-term nicotine replacement therapy: a randomized clinical trial. *JAMA Intern Med.* 2015;175(4):504-11.
262. Schnoll R, Leone F, Veluz-Wilkins A, Miele A, Hole A, Jao NC, et al. A randomized controlled trial of 24 weeks of varenicline for tobacco use among cancer patients: Efficacy, safety, and adherence. *Psychooncology.* 2019;28(3):561-9.
263. Schuurmans MM, Diacon AH, van Biljon X, Bolliger CT. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial. *Addiction.* 2004;99(5):634-40.
264. Selby P BBSN. Retreatment with ZYban SR: 52 week follow-up of a Canadian Multicentre trial (POS3-63). 2003.
265. Selma Bozkurt Z, Serkan Z, Esra K, Esra Aydin S. Comparison of the effectiveness of varenicline, extended-release bupropion and nicotine replacement therapy on the success and the maintenance of a smoking cessation program. *Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology.* 2013;23(3):224-30.
266. Severson HH, Danaher BG, Ebbert JO, van Meter N, Lichtenstein E, Widdop C, et al. Randomized trial of nicotine lozenges and phone counseling for smokeless tobacco cessation. *Nicotine Tob Res.* 2015;17(3):309-15.

267. Sharma SK, Mohan A, Singh AD, Mishra H, Jhanjee S, Pandey RM, et al. Impact of nicotine replacement therapy as an adjunct to anti-tuberculosis treatment and behaviour change counselling in newly diagnosed pulmonary tuberculosis patients: an open-label, randomised controlled trial. *Sci Rep*. 2018;8(1):8828.
268. Sheng LX, Tang YL, Jiang ZN, Yao CH, Gao JY, Xu GZ, et al. Sustained-release bupropion for smoking cessation in a Chinese sample: a double-blind, placebo-controlled, randomized trial. *Nicotine Tob Res*. 2013;15(2):320-5.
269. Sherman SE, Aldana I, Estrada M, York L. Comparing the tolerability and effectiveness of two treatment regimens in a smoking clinic. *Mil Med*. 2008;173(6):550-4.
270. Shiffman S, Dresler CM, Hajek P, Gilbert SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. *Arch Intern Med*. 2002;162(11):1267-76.
271. Shiffman S, Scharf DM, Shadel WG, Gwaltney CJ, Dang Q, Paton SM, et al. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. *J Consult Clin Psychol*. 2006;74(2):276-85.
272. Shiffman S, Ferguson SG, Strahs KR. Quitting by gradual smoking reduction using nicotine gum: a randomized controlled trial. *Am J Prev Med*. 2009;36(2):96-104 e1.
273. Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, et al. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. *Neuropsychopharmacology*. 2012;37(3):660-8.
274. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. *Drug Alcohol Depend*. 2008;96(3):222-32.
275. Siddiqi K, Khan A, Ahmad M, Dogar O, Kanaan M, Newell JN, et al. Action to stop smoking in suspected tuberculosis (ASSIST) in Pakistan: a cluster randomized, controlled trial. *Ann Intern Med*. 2013;158(9):667-75.
276. Simon JA, Solkowitz SN, Carmody TP, Browner WS. Smoking cessation after surgery. A randomized trial. *Arch Intern Med*. 1997;157(12):1371-6.
277. Simon JA, Duncan C, Carmody TP, Hudes ES. Bupropion for smoking cessation: a randomized trial. *Arch Intern Med*. 2004;164(16):1797-803.
278. Simon JA, Duncan C, Huggins J, Solkowitz S, Carmody TP. Sustained-release bupropion for hospital-based smoking cessation: a randomized trial. *Nicotine Tob Res*. 2009;11(6):663-9.
279. Singh P, Kumar R. Assessment of the effectiveness of sustained release Bupropion and intensive physician advice in smoking cessation. *Lung India*. 2010;27(1):11-8.
280. Smith SS, McCarthy DE, Japuntich SJ, Christiansen B, Piper ME, Jorenby DE, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. *Arch Intern Med*. 2009;169(22):2148-55.
281. Smith RC, Amiaz R, Si TM, Maayan L, Jin H, Boules S, et al. Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. *PLoS One*. 2016;11(1):e0143490.
282. ZYB40005: The effect of sustained-release bupropion HCl vs. placebo as an aid to smoking reduction leading to cessation among smokers unwilling and unable to quit smoking.
283. Sonderskov J, Olsen J, Sabroe S, Meillier L, Overvad K. Nicotine patches in smoking cessation: A randomized trial among over-the-counter customers in Denmark. *American Journal of Epidemiology*. 1997;145(4):309-18.
284. Sorensen LT, Jorgensen T. Short-term pre-operative smoking cessation intervention does not affect postoperative complications in colorectal surgery: a randomized clinical trial. *Colorectal Dis*. 2003;5(4):347-52.
285. Southern Illinois University Carbondale, National Institute on Drug Abuse. Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers. <https://ClinicalTrials.gov/show/NCT01048944>; 2005.
286. Stanford University, Pfizer. Varenicline In-Patient Study. <https://ClinicalTrials.gov/show/NCT01413516>; 2011.
287. Stapleton JA, Russell MA, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U, et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. *Addiction*. 1995;90(1):31-42.
288. Stapleton JA, Sutherland G. Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo-controlled trial. *Addiction*. 2011;106(4):824-32.
289. Stapleton J, West R, Hajek P, Wheeler J, Vangeli E, Abdi Z, et al. Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. *Addiction*. 2013;108(12):2193-201.

290. Stein MD, Caviness CM, Kurth ME, Audet D, Olson J, Anderson BJ. Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. *Drug Alcohol Depend.* 2013;133(2):486-93.
291. Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, et al. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. *Ann Intern Med.* 2009;150(7):447-54.
292. Steinberg MB, Randall J, Greenhaus S, Schmelzer AC, Richardson DL, Carson JL. Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline. *Addict Behav.* 2011;36(12):1127-32.
293. Steinberg ML, Lu SE, Williams JM. Varenicline for smoking reduction in smokers not yet ready to quit: A double-blind, proof-of-concept randomized clinical trial. *Addict Behav.* 2018;84:20-6.
294. Sutherland G, Stapleton JA, Russell MAH, Jarvis MJ, Hajek P, Belcher M, et al. Randomized Controlled Trial of Nasal Nicotine Spray in Smoking Cessation. *Lancet.* 1992;340(8815):324-9.
295. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. *Arch Intern Med.* 2003;163(19):2337-44.
296. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. *Lancet.* 2001;357(9268):1571-5.
297. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. *Chest.* 2011;139(3):591-9.
298. Thomsen T, Tonnesen H, Okholm M, Kroman N, Maibom A, Sauerberg ML, et al. Brief smoking cessation intervention in relation to breast cancer surgery: a randomized controlled trial. *Nicotine Tob Res.* 2010;12(11):1118-24.
299. Thorsteinsson HS, Gillin JC, Patten CA, Golshan S, Sutton LD, Drummond S, et al. The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression. *Neuropsychopharmacology.* 2001;24(4):350-8.
300. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Reid N. Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. *Psychopharmacology (Berl).* 2011;217(2):279-87.
301. Tonnesen P, Fryd V, Hansen M, Helsted J, Gunnensen AB, Forchammer H, et al. Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking. *N Engl J Med.* 1988;318(1):15-8.
302. Tonnesen P, Fryd V, Hansen M, Helsted J, Gunnensen AB, Forchammer H, et al. Two and four mg nicotine chewing gum and group counselling in smoking cessation: an open, randomized, controlled trial with a 22 month follow-up. *Addict Behav.* 1988;13(1):17-27.
303. Tonnesen P, Norregaard J, Simonsen K, Sawe U. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. *N Engl J Med.* 1991;325(5):311-5.
304. Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. *JAMA.* 1993;269(10):1268-71.
305. Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. *Eur Respir J.* 1999;13(2):238-46.
306. Tonnesen P, Mikkelsen KL. Smoking cessation with four nicotine replacement regimes in a lung clinic. *Eur Respir J.* 2000;16(4):717-22.
307. Tonnesen P, Tonstad S, Hjalmarsen A, Leborgy F, Van Spiegel PI, Hider A, et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. *J Intern Med.* 2003;254(2):184-92.
308. Tonnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. *Chest.* 2006;130(2):334-42.
309. Tonnesen P, Lauri H, Perfekt R, Mann K, Batra A. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. *Eur Respir J.* 2012;40(3):548-54.
310. Tonstad S, Farsang C, Klaene G, Lewis K, Manolis A, Perruchoud AP, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. *Eur Heart J.* 2003;24(10):946-55.
311. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. *JAMA.* 2006;296(1):64-71.

312. Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB, Jr., et al. A randomized, placebo-controlled trial of varenicline, a selective $\alpha 4\beta 2$ nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. *Clin Ther.* 2007;29(6):1027-39.
313. Tseng TY, Ostroff JS, Campo A, Gerard M, Kirchner T, Rotrosen J, et al. A Randomized Trial Comparing the Effect of Nicotine Versus Placebo Electronic Cigarettes on Smoking Reduction Among Young Adult Smokers. *Nicotine Tob Res.* 2016;18(10):1937-43.
314. Tsukahara H, Noda K, Saku K. A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study). *Circ J.* 2010;74(4):771-8.
315. Tuisku A, Salmela M, Nieminen P, Toljamo T. Varenicline and Nicotine Patch Therapies in Young Adults Motivated to Quit Smoking: A Randomized, Placebo-controlled, Prospective Study. *Basic Clin Pharmacol Toxicol.* 2016;119(1):78-84.
316. Tulloch HE, Pipe AL, Els C, Clyde MJ, Reid RD. Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial. *BMC Med.* 2016;14(80):80.
317. Tzivoni D, Keren A, Meyler S, Khoury Z, Lerer T, Brunel P. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. *Cardiovasc Drugs Ther.* 1998;12(3):239-44.
318. University of Michigan, National Heart LaBI. A Randomized Trial of Internet Access to Nicotine Patches. <https://ClinicalTrials.gov/show/NCT00534404>; 2011.
319. Uyar M, Filiz A, Bayram N, Elbek O, Herken H, Topcu A, et al. A randomized trial of smoking cessation. Medication versus motivation. *Saudi Med J.* 2007;28(6):922-6.
320. Velicer WF, Friedman RH, Fava JL, Gulliver SB, Keller S, Sun X, et al. Evaluating nicotine replacement therapy and stage-based therapies in a population-based effectiveness trial. *J Consult Clin Psychol.* 2006;74(6):1162-72.
321. Verplaetse TL, Pittman BP, Shi JM, Tetrault JM, Coppola S, McKee SA. Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders. *J Addict Med.* 2016;10(3):166-73.
322. Wagena EJ, Knipschild PG, Huibers MJH, Wouters EFM, Schayck CPR. Efficacy of bupropion and nortriptyline for smoking cessation among people who are at risk for or have chronic obstructive pulmonary disease: Results from a randomized, placebo-controlled trial. *Nicotine & Tobacco Research.* 2005;7(4):683-4.
323. Wallstrom M, Nilsson F, Hirsch JM. A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation. *Addiction.* 2000;95(8):1161-71.
324. Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. *Respirology.* 2009;14(3):384-92.
325. Ward KD, Asfar T, Al Ali R, Rastam S, Weg MW, Eissenberg T, et al. Randomized trial of the effectiveness of combined behavioral/pharmacological smoking cessation treatment in Syrian primary care clinics. *Addiction.* 2013;108(2):394-403.
326. Warner DO, Patten CA, Ames SC, Offord KP, Schroeder DR. Effect of nicotine replacement therapy on stress and smoking behavior in surgical patients. *Anesthesiology.* 2005;102(6):1138-46.
327. Weaver K, Kaplan S, Urbanic J, Case D, Zbikowski S, Dakhil C, et al. Incorporating evidence-based smoking cessation into community oncology practices: Feasibility and preliminary efficacy of an enhanced quitline-based smoking cessation intervention for cancer survivors 2015; 24:[32 p.]. Available from: <http://onlinelibrary.wiley.com/doi/10.1111/1471-2575.12500>.
328. Weinberger AH, Vessicchio JC, Sacco KA, Creeden CL, Chengappa KN, George TP. A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder. *J Clin Psychopharmacol.* 2008;28(5):584-7.
329. Weiner E, Buchholz A, Coffay A, Liu F, McMahon RP, Buchanan RW, et al. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. *Schizophr Res.* 2011;129(1):94-5.
330. Weiner E, Ball MP, Buchholz AS, Gold JM, Evins AE, McMahon RP, et al. Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. *J Clin Psychiatry.* 2012;73(1):95-102.
331. Wennike P, Danielsson T, Landfeldt B, Westin A, Tonnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. *Addiction.* 2003;98(10):1395-402.
332. Westergaard CG, Porsbjerg C, Backer V. The effect of Varenicline on smoking cessation in a group of young asthma patients. *Respir Med.* 2015;109(11):1416-22.

333. Westman EC, Levin ED, Rose JE. The nicotine patch in smoking cessation. A randomized trial with telephone counseling. *Arch Intern Med.* 1993;153(16):1917-23.
334. Whelton H, Kingston R, O'Mullane D, Nilsson F. Randomized controlled trial to evaluate tooth stain reduction with nicotine replacement gum during a smoking cessation program. *BMC Oral Health.* 2012;12(13):13.
335. Wiggers LC, Smets EM, Oort FJ, Peters RJ, Storm-Versloot MN, Vermeulen H, et al. The effect of a minimal intervention strategy in addition to nicotine replacement therapy to support smoking cessation in cardiovascular outpatients: a randomized clinical trial. *Eur J Cardiovasc Prev Rehabil.* 2006;13(6):931-7.
336. Williams KE, Reeves KR, Billing CB, Jr., Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. *Curr Med Res Opin.* 2007;23(4):793-801.
337. Williams JM, Anthenelli RM, Morris CD, Treadow J, Thompson JR, Yunis C, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. *J Clin Psychiatry.* 2012;73(5):654-60.
338. Wilson JS, Fitzsimons D, Bradbury I, Stuart Elborn J. Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. *Int J Nurs Stud.* 2008;45(4):508-17.
339. Winhusen TM, Brigham GS, Kropp F, Lindblad R, Gardin JG, 2nd, Penn P, et al. A randomized trial of concurrent smoking-cessation and substance use disorder treatment in stimulant-dependent smokers. *J Clin Psychiatry.* 2014;75(4):336-43.
340. Wiratmoko MR, Yunus F, Susanto AD, Ginting TT, Kekalih A. Efficacy of Varenicline, an Nicotinic Acetylcholine Receptor Partial Agonist, Vs Placebo for Smoking Cessation. A Randomized Controlled Trial. *Respirology.* 2013;18:66-.
341. Wittchen HU, Hoch E, Klotsche J, Muehlig S. Smoking cessation in primary care - a randomized controlled trial of bupropione, nicotine replacements, CBT and a minimal intervention. *Int J Methods Psychiatr Res.* 2011;20(1):28-39.
342. Wolfenden L, Wiggers J, Knight J, Campbell E, Rissel C, Kerridge R, et al. A programme for reducing smoking in pre-operative surgical patients: randomised controlled trial. *Anaesthesia.* 2005;60(2):172-9.
343. Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD. A randomized trial of naltrexone for smoking cessation. *Addiction.* 1999;94(8):1227-37.
344. Wong J, Abrishami A, Yang Y, Zaki A, Friedman Z, Selby P, et al. A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial. *Anesthesiology.* 2012;117(4):755-64.
345. Wong J, Abrishami A, Riazi S, Siddiqui N, You-Ten E, Korman J, et al. A Perioperative Smoking Cessation Intervention With Varenicline, Counseling, and Fax Referral to a Telephone Quitline Versus a Brief Intervention: A Randomized Controlled Trial. *Anesth Analg.* 2017;125(2):571-9.
346. Yale University, National Institute on Alcohol Abuse and Alcoholism. The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior. <https://ClinicalTrials.gov/show/NCT00580853>; 2007.
347. Zellweger JP, Boelcskei PL, Carrozzi L, Sepper R, Sweet R, Hider AZ. Bupropion SR vs placebo for smoking cessation in health care professionals. *Am J Health Behav.* 2005;29(3):240-9.
348. Zernig G, Wallner R, Grohs U, Kriechbaum N, Kemmler G, Saria A. A randomized trial of short psychotherapy versus sustained-release bupropion for smoking cessation. *Addiction.* 2008;103(12):2024-31.
349. Zhu J. The effectiveness of bupropion SR on depressive symptoms in smokers: Self-reports, EEG, and individual differences. *Dissertation Abstracts International: Section B: The Sciences and Engineering.* 2016;77(3-B(E)):No Pagination Specified.
350. ZYB40030: a multi-centre, randomised, double-blind, placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release versus placebo as an aid to smoking cessation in a population of smokers with chronic obstructive pulmonary disease.
351. ZYB 30011: A multicentre, randomised, double-blind, placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release (2 x 150mg per day) versus placebo as an aid to smoking cessation in smokers with at least one cardiovascular (CV) risk factor.
352. SMK20001: A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group, Dose Response Evaluation of a New Chemical Entity (NCE) and ZYBAN (bupropion hydrochloride) Sustained Release (300mg/day) versus Placebo As Aids to Smoking Cessation.